Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Trial

is that when the Patent was re-examined it changed the patent and argue that domestic industry should be evaluated from that point on. Our original motion was denied because we failed to address this concept in a timely manner. I think this concept will fail. Not all the claims were changed and the 336 as whole was substantially unchanged. I don't think Domestic Industry will be a deciding factor in this case. IMO

Share
New Message
Please login to post a reply